BR112022026508A2 - Anticorpos que reconhecem sortilina - Google Patents
Anticorpos que reconhecem sortilinaInfo
- Publication number
- BR112022026508A2 BR112022026508A2 BR112022026508A BR112022026508A BR112022026508A2 BR 112022026508 A2 BR112022026508 A2 BR 112022026508A2 BR 112022026508 A BR112022026508 A BR 112022026508A BR 112022026508 A BR112022026508 A BR 112022026508A BR 112022026508 A2 BR112022026508 A2 BR 112022026508A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- sortilin
- recognize
- delay
- changes
- Prior art date
Links
- 102100032889 Sortilin Human genes 0.000 title abstract 3
- 108010014657 sortilin Proteins 0.000 title abstract 3
- 102000019204 Progranulins Human genes 0.000 abstract 1
- 108010012809 Progranulins Proteins 0.000 abstract 1
- 230000006866 deterioration Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
ANTICORPOS QUE RECONHECEM SORTILINA. A invenção fornece anticorpos que se ligam especificamente à sortilina. Os anticorpos inibem ou retardam as patologias associadas a alterações nos níveis de progranulina e deterioração sintomática associada.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063043481P | 2020-06-24 | 2020-06-24 | |
PCT/US2021/070764 WO2021263279A1 (en) | 2020-06-24 | 2021-06-23 | Antibodies recognizing sortilin |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022026508A2 true BR112022026508A2 (pt) | 2023-03-07 |
Family
ID=79281994
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022026508A BR112022026508A2 (pt) | 2020-06-24 | 2021-06-23 | Anticorpos que reconhecem sortilina |
Country Status (12)
Country | Link |
---|---|
US (3) | US20230235048A1 (pt) |
EP (1) | EP4171743A4 (pt) |
JP (1) | JP2023533458A (pt) |
KR (1) | KR20230026489A (pt) |
CN (1) | CN116249717A (pt) |
AR (1) | AR122736A1 (pt) |
AU (1) | AU2021297540A1 (pt) |
BR (1) | BR112022026508A2 (pt) |
CA (1) | CA3183994A1 (pt) |
IL (1) | IL299329A (pt) |
TW (1) | TW202216773A (pt) |
WO (1) | WO2021263279A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL299329A (en) | 2020-06-24 | 2023-02-01 | Prothena Biosciences Ltd | Antibodies recognizing sortilin |
WO2023122766A2 (en) * | 2021-12-23 | 2023-06-29 | Prothena Biosciences Limited | Antibodies recognizing sortilin |
WO2023247754A1 (en) | 2022-06-23 | 2023-12-28 | Draupnir Bio Aps | Bifunctional molecules that selectively induce degradation of extracellular targets in lysosomes |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
JPH06508511A (ja) | 1990-07-10 | 1994-09-29 | ケンブリッジ アンティボディー テクノロジー リミティド | 特異的な結合ペアーの構成員の製造方法 |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5674703A (en) | 1992-12-02 | 1997-10-07 | Woo; Savio L. C. | Episomal vector systems and related methods |
ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
WO1995007707A1 (en) | 1993-09-14 | 1995-03-23 | Cytel Corporation | Alteration of immune response using pan dr-binding peptides |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5877218A (en) | 1994-01-10 | 1999-03-02 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
AUPO390396A0 (en) | 1996-11-29 | 1996-12-19 | Csl Limited | Novel promiscuous T helper cell epitopes |
PT1005368E (pt) | 1997-03-10 | 2009-11-19 | Coley Pharm Gmbh | Utilização de ácidos nucleicos contendo dinucleótidos cpg não metilados em combinação com alúmen como adjuvante |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
EP2298809A3 (en) | 2001-07-12 | 2012-02-15 | FOOTE, Jefferson | Super humanized antibodies |
DE60220719T2 (de) | 2001-12-28 | 2008-03-06 | Amgen Fremont Inc. | Antikörper gegen das muc18-antigen |
WO2004050884A2 (de) | 2002-11-29 | 2004-06-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue neomycin-phosphotransferase-gene und verfahren zur selektion von hochproduzierenden rekombinanten zellen |
DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
WO2006051065A2 (en) | 2004-11-10 | 2006-05-18 | Boehringer Ingelheim Pharma Gmbh & Co.Kg | Use of flow-cytometric analysis to optimize cell banking strategies for cho cells |
EP2215450B1 (en) * | 2006-02-21 | 2013-07-31 | Nexus DX, Inc. | Methods and compositions for analyte detection |
US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
ES2523915T5 (es) | 2006-12-01 | 2022-05-26 | Seagen Inc | Agentes de unión a la diana variantes y usos de los mismos |
PT2099826E (pt) | 2007-01-05 | 2014-01-09 | Univ Zuerich | Anticorpo anti-beta-amilóide e suas utilizações |
AR065573A1 (es) | 2007-03-02 | 2009-06-17 | Boehringer Ingelheim Int | Metodo de produccion de proteinas heterologas por expresion de una proteina con dominio de trasnferencia de lipido relacionada con proteina reguladora de la esteroidogenesis aguda start. |
EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
CN102711449B (zh) * | 2009-12-10 | 2015-01-07 | 瑞泽恩制药公司 | 生产重链抗体的小鼠 |
CN106279416B (zh) * | 2010-03-04 | 2019-08-30 | 宏观基因有限公司 | 与b7-h3反应性的抗体、其免疫学活性片段及其用途 |
WO2013164689A2 (en) * | 2012-05-02 | 2013-11-07 | Lantto, Johan | Humanized pan-her antibody compositions |
TWI769570B (zh) | 2015-01-28 | 2022-07-01 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
IL254887B2 (en) * | 2015-04-07 | 2023-11-01 | Alector Llc | Anti-sortilin antibodies and methods of using them |
GB201512215D0 (en) * | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
CN108137702B (zh) | 2015-08-28 | 2023-01-06 | 艾利妥 | 抗siglec-7抗体及其使用方法 |
CA3004349A1 (en) | 2015-11-23 | 2017-06-01 | Sangamo Therapeutics, Inc. | Methods and compositions for engineering immunity |
US10894833B2 (en) * | 2017-07-20 | 2021-01-19 | H. Lundbeck A/S | Agents, uses and methods for treatment |
JP7393337B2 (ja) | 2018-02-11 | 2023-12-06 | 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 | 抗b7-h4抗体、その抗原結合断片及びその医薬用途 |
IL299329A (en) | 2020-06-24 | 2023-02-01 | Prothena Biosciences Ltd | Antibodies recognizing sortilin |
WO2023122766A2 (en) | 2021-12-23 | 2023-06-29 | Prothena Biosciences Limited | Antibodies recognizing sortilin |
-
2021
- 2021-06-23 IL IL299329A patent/IL299329A/en unknown
- 2021-06-23 CA CA3183994A patent/CA3183994A1/en active Pending
- 2021-06-23 EP EP21829181.3A patent/EP4171743A4/en active Pending
- 2021-06-23 KR KR1020237002522A patent/KR20230026489A/ko active Search and Examination
- 2021-06-23 JP JP2022579951A patent/JP2023533458A/ja active Pending
- 2021-06-23 CN CN202180051773.0A patent/CN116249717A/zh active Pending
- 2021-06-23 AU AU2021297540A patent/AU2021297540A1/en active Pending
- 2021-06-23 WO PCT/US2021/070764 patent/WO2021263279A1/en active Application Filing
- 2021-06-23 BR BR112022026508A patent/BR112022026508A2/pt unknown
- 2021-06-23 US US18/011,764 patent/US20230235048A1/en active Pending
- 2021-06-24 TW TW110123220A patent/TW202216773A/zh unknown
- 2021-06-24 AR ARP210101748A patent/AR122736A1/es unknown
-
2023
- 2023-10-26 US US18/384,223 patent/US12049497B2/en active Active
- 2023-10-26 US US18/384,230 patent/US12049498B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP4171743A1 (en) | 2023-05-03 |
KR20230026489A (ko) | 2023-02-24 |
US20240117039A1 (en) | 2024-04-11 |
US12049497B2 (en) | 2024-07-30 |
JP2023533458A (ja) | 2023-08-03 |
WO2021263279A1 (en) | 2021-12-30 |
AR122736A1 (es) | 2022-10-05 |
CA3183994A1 (en) | 2021-12-30 |
US12049498B2 (en) | 2024-07-30 |
IL299329A (en) | 2023-02-01 |
TW202216773A (zh) | 2022-05-01 |
US20240117040A1 (en) | 2024-04-11 |
EP4171743A4 (en) | 2024-07-24 |
US20230235048A1 (en) | 2023-07-27 |
CN116249717A (zh) | 2023-06-09 |
AU2021297540A1 (en) | 2023-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022026508A2 (pt) | Anticorpos que reconhecem sortilina | |
BR112021016947A2 (pt) | Anticorpos que reconhecem tau | |
BR112019022906A2 (pt) | Anticorpos que reconhecem tau | |
BR112018072389A2 (pt) | anticorpos que reconhecem tau | |
BR112022017930A2 (pt) | Anticorpos anticoronavírus e métodos de uso | |
CO2021011140A2 (es) | Anticuerpos que reconocen tau | |
BR112018072394A2 (pt) | anticorpos que reconhecem a tau | |
CU24446B1 (es) | Un anticuerpo monoclonal humanizado que se une a tau | |
EA202190542A1 (ru) | Сконструированные биспецифические белки | |
AR101846A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
CO2021007370A2 (es) | Anticuerpos que reconocen tau | |
BR112019004990A2 (pt) | anticorpo que se liga especificamente a il-17a e fragmento funcional do mesmo | |
CU20210039A7 (es) | Anticuerpos que reconocen tau | |
BR112016020366A2 (pt) | anticorpos anti-eotaxina-2 que reconhecem quimiocinas de ligação a ccr3 adicionais | |
BR112021004316A2 (pt) | Anticorpos de agonistas anti-trem-2 | |
BR112021013397A2 (pt) | Anticorpos anti-tigit | |
EP3773716A4 (en) | MONOCLONAL ANTIBODIES THAT BIND TO SSEA4 AND THEIR USES | |
AR128076A1 (es) | Anticuerpos que reconocen la sortilina | |
CL2020002459A1 (es) | Variantes de anticuerpo c-terminales | |
EA202190772A1 (ru) | Панельный элемент | |
PE20230602A1 (es) | Anticuerpos anti-sea de muc1 | |
BR112017015181A2 (pt) | membros elastoméricos para um amortecedor de vibração torsional, método para fazer um membro elastomérico para um amortecedor de vibração torsional, amortecedor de vibração torsional | |
MA55035A (fr) | Commutateur de robinet de vidange doté d'une structure d'embrayage, et robinet de vidange | |
MA52966A (fr) | Anticorps anti-facteur xii/xiia et leurs utilisations | |
EA202192113A1 (ru) | Антитела, распознающие тау |